

CURRICULUM VITAE

**Thomas E. Bak, M.D.**  
*Associate Professor of Surgery*  
*Division of Transplant Surgery*

**EDUCATION:**

**University of Texas; Austin, TX**  
Degree and Date: B.A. in Zoology/Physiology  
Awarded with High Honors, 1988

**Georgetown University; Washington, D.C.**  
Program: Institute of Comparative Economic and Political  
Systems, Summer, 1986

**Jagellonian University; Cracow, Poland**  
Program: Kosciuszko Foundation for Polish Studies,  
Summer, 1987

**Tulane University School of Medicine; New Orleans, LA**  
Degree and Date: M.D., June, 1992  
Class Rank: Upper one-quarter of class

**University of Colorado Health Sciences Center; Denver, CO**  
Program: General Surgical Residency  
June 1992 to July 1998

**University of Colorado Health Sciences Center; Denver, CO**  
Program: Fellowship, Transplantation  
July 1998 to Jan 2000

**Present Position:** **University of Colorado Health Sciences Center; Denver, CO**  
Associate Professor of Surgery  
Division of Transplant Surgery  
Jan 2000 to Present

**Presbyterian St. Lukes Transplant Center; Denver, CO**  
Surgical Director  
June 2007 to Present

**Honors/Awards:**

### Medical School

Recipient of Tulane University School of Medicine Merit Scholarship, 1988-1992  
Rank in top quarter of medical school class  
Honors in Clinical Surgery course

### Undergraduate

Graduated with High Honors, 1988  
Dean's list, College of Natural Sciences, Six semesters  
Member of Phi Beta Kappa, Phi Kappa Phi Honor Societies  
Elected to Golden Key Society, Beta Beta Beta, Phi Eta Sigma and Alpha Lambda Delta Honor Societies  
Silver Medallist; Captain, U.S.A Basketball Team  
International Polonia Olympiad, Cracow, Poland, 1987

### Activities/Organizations:

2000-Present	Member, European Renal Association
1999-Present	Member, International Hepatobiliary Association
2002-Present	Denver Academy of Surgery
2002-Present	American Society of Transplant Surgeons
2001-Present	International Liver Transplant Surgeons

### Committees

1999-2004	Member, UCHSC, Antimicrobial Subcommittee
1998-Present	Member, Medical Advisory Committee, Donor Alliance
2000-Present	Member, Coroner Protocol Review Committee
2001-Present	Liver Transplant Selection Committee
2001-Present	Kidney and Pancreas Transplant Selection Committee

### Licensure & Certifications

1994	State of Colorado
1999	American Board of Surgery

**Languages:** Polish

### Publications:

1. Bennet W, Zimmerman MA, Campsen J, Mandell MS, **Bak T**, Wachs M, Kam I. Choledochoduodenostomy is a safe alternative to roux-en-y

- choledochojejunostomy for biliary reconstruction in liver transplantation. *World J Surg.* 2009;33:1022-1025.
2. Campsen, J, Zimmerman MA, Trotter JF, Wachs M, **Bak T**, Steinberg T, Kaplan M, Wright F, Kam I. Liver Transplantation for Autoimmune Hepatitis and the Success of Aggressive Corticosteroid withdrawal. *Liver Transplantation*, 14:1281-1286, September 2008.
  3. Zimmerman MA, Trotter JF, Wachs M, **Bak T**, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: A single-center experience. *Transpl Int* 2007;29:747-753.
  4. Campsen J, Zimmerman M, Trotter JF, Wachs M, **Bak T**, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. *Expert Opinion Pharmacother*, 8(9):1275-1282, 2007.
  5. J.F. Trotter, J. Campsen, **T. Bak**, M. Wachs, L. Forman, G. Everson and I. Kam. Outcomes of Donor Evaluations for Adult-to-Adult Right Hepatic Lobe Living Donor Liver Transplantation. *American Journal of Transplantation*, 6:1882-1889, 2006.
  6. Campsen J, Hendrickson R, **Bak T**, Wachs M, Kam I, Nash R, Russ R and Levi M. Herpes simplex in a liver transplant recipient. *Liver Transplantation*, 12:1171-1173, July 2006.
  7. Slater K, Ludkowski M, Mehling J, Forman L, Pieramici E, Wachs ME, Kam I and **Bak TE**. Hepatic artery pseudoaneurysm – duodenal fistula after living donor liver transplant. *Clin Transplant* 2004; 18:734-736.
  8. Hendrickson RJ, Karrer FM, Wachs ME, Slater K, **Bak T** and Kam I. Pediatric liver transplantation. *Current Opinion in Pediatrics*, 16:309-313, 2004.
  9. Slater K, **Bak TE**, Kam I, Wachs ME. Living donor liver transplant for fibrolamellar hepatocellular carcinoma using a deceased donor graft to reconstruct inferior vena cava. *Liver Transplantation*, 10(4):555-556, April 2004.
  10. Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M, **Bak T**, Kam I, Everson GT. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. *Liver Transplantation*, 10(1):42-48, January 2004.
  11. Kugelmas M, Osgood MJ, Trotter JF, **Bak T**, Wachs M, Forman L, Kam I, Everson GT. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. *Liver Transplantation* 9(11): 1159-65, November 2003.
  12. Kugelmas M, Spiegelman M, Osgood M, Young D, Trotter J, Steinberg T, Wachs M, **Bak T**, Kam I and Everson G. Different immunosuppressive regimens and

- recurrence of primary sclerosing cholangitis after liver transplantation. *Liver Transplantation* 9(7);727-736, July 2003.
13. A.C. Wiseman, I. Kam, U. Christians, A. Jani, **T. Bak**, M. Wachs, and L. Chan. Fixed-dose Sirolimus with reduced dose Calcineurin Inhibitor: The University of Colorado Experience. *Transplant Proceedings* Vol. 9 (Suppl 3A), 122S-124S (May 2003).
  14. Dunkelberg J, Trotter J, Wachs M, **Bak T**, Kugelmas M, Steinberg T, Everson G and I. Kam. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. *Liver Transplantation* Vol. 9(5):463-468, May 2003.
  15. A.C. Wiseman, L. Chan, U. Christians, A. Jani, **T. Bak**, M. Wachs, and I. Kam. Fixed dose Sirolimus with reduced dose calcinerurin inhibitor : The University of Colorado Experience. *Transplant Proceedings* 35 (Suppl 3A), 000S (2003).
  16. Trotter JF, Mackenzie S, Wachs M, **Bak T**, Steinberg T, Polsky P, Kam I, Everson GT. Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation. *Transplantation* 2003 Feb., Vol 27;75(4):473-6.
  17. Trotter J, Stolpman N, Wachs M, **Bak T**, Kugelmas, Kam I, Everson G. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. *Liver Transplantation* 8(3):212-218, March 2002.
  18. Trotter J, Everson G, Back S, Wachs M, **Bak T**, Kam I. Transference of peanut allergy through liver transplantation. *Liver Transplantation* 7(12): 1088-1089, December 2001.
  19. Wachs M, Trotter J, **Bak T**, Kam I. Living donor liver transplantation: surgical considerations. *Current Opinion in Organ Transplant* 2001, 6:359-362.
  20. **Bak T**, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, Steinberg T, Kam I. Adult-to-adult living donor liver transplant using right lobe grafts: results and lessons learned from a single center experience. *Liver Transplantation* 7(8): 680-686, August 2001.
  21. Trotter J, Talamantes M, McClure M, Wachs M, **Bak T**, Trouillot T, Kugelmas M, Everson E, Kam I. Right hepatic lobe donation for living donor liver transplantation: Impact on donor quality of life. *Liver Transplantation* 7(6):485-493, June 2001

22. Trotter J, Wachs M, Trouillot T, **Bak T**, Kugelmas K, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. *Liver Transplantation* 7(5):401-408, May 2001.
23. Trotter J, Wachs M, **Bak T**, Trouillot T, Stolpman N, Everson G, Kam I. Liver transplantation using Sirolimus and minimal Corticosteroids (3-day taper). *Liver Transplantation* 7(4):343-351, April 2001.
24. Trotter JF, **Bak T**, Wachs M, Everson GT, Kam I. Combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus. *Transplantation* 70(8):1-3, August, 2000.
25. Trotter J, Wachs M, Trouillot T, Steinberg T, **Bak T**, Everson G, Kam I. Evaluation of 100 patients for living donor liver transplantation. *Liver Transplantation and Surgery* 6(3):290-295, May 2000.
26. Everson GT, Trouillot T, Wachs M, **Bak T**, Steinberg T, Kam I, Shrestha R, Stegal M. Early steroid withdrawal in liver transplantation is safe and beneficial. *Liver Transplantation and Surgery* 5(4):S48-S57, July 1999.
27. Wachs ME, **Bak TE**, Karrer FM, Everson GT, Shrestha R, Trouillot TE, Mandell S, Steinberg T, Kam I. Adult Living Donor Liver Transplantation using a Right Hepatic Lobe. *Transplantation* Vol 66, No. 10, November 1998; 1313-1316.

**Abstracts/ Presentations:**

1. Taniguchi M, Wachs M, **Bak T**, Trotter J, Kugelmas M, Everson G, Kam I. Hepatitis C recurrence in living donor liver transplantation. *Am J Transpl* 2002;2(suppl 2):138.
2. **Thomas Bak**, University of Colorado Health Sciences Center. Living Donor Liver Transplant: The Middle Hepatic Vein. Presented at the *Controversies in Transplantation* Retreat. Breckenridge, Colorado, March 8-10, 2002.
3. **Thomas Bak**, University of Colorado Health Sciences Center. Living Donor Liver Transplant at the University of Colorado. Presented at the William-Labadie Grand Rounds for Dr. Jay Cashman. Phoenix, Arizona, November, 2001.
4. **Thomas Bak**, University of Colorado Health Sciences Center. Living Donor Transplant at the University of Colorado Hospital. Presented at the Good Samaritan Hospital for Wyeth-Ayerst Pharmaceuticals. Phoenix, Arizona, May 3, 2001.

5. **Bak T**, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, Steinberg T, Kam I. Adult-to-adult living donor liver transplantation using right-lobe grafts: Results and lessons learned from a single-center experience. *ASTS Meeting* 2001.
6. **Thomas Bak**, University of Colorado Health Sciences Center. “Building Awareness & Acceptance of Cyclosporine AB in the Transplant Physician Community” invitational advisory board member. SidMak Laboratories, Inc. Dallas, Texas, March 30- April 1, 2001.
7. **Thomas Bak**, University of Colorado Health Sciences Center. Immunosuppression and Renal Transplantation: Laparoscopic donor nephrectomy. Presented at the *Controversies in Transplantation* Retreat. Breckenridge, Colorado, March 9-11, 2001.
8. Stolpman N, Kam I, Wachs M, **Bak T**, Trouillot T, Trotter J, Steinberg T, Stephens J, Everson GT. Mycophenolated Mofetil does Not Lower the Incidence or Cost of Rejection, Use of OKT3, or improve survival after liver transplantation and rapid (14d) steroid withdrawal. *AASLD Annual Meeting*, October, 2000.
9. Trotter J, Wachs M, Trouillot T, **Bak T**, Everson GT, Kam I, Division of Gastroenterology and Haepatology, Division on Transplant Surgery, university of Colorado Health Sciences Center. The effect of Living Donor Liver Transplantation (LDLT) on Median Waiting Times for UNOS Status IIB Cadaveric Recipients at One Center. *AASLD Annual Meeting*, October, 2000.
10. Trouillot T, Stolpman N, Wachs M, **Bak T**, Trotter J, Kam I, Everson GT, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Mycophenolate Mofetil-Based Immunosuppression does not increase the risk of Cytomegalovirus disease in patients treated with Rapdi (14d) steroid withdrawal after liver transplantation. *AASLD Annual Meeting*, October, 2000.
11. Heimbach J, Wachs M, **Bak T**, Steinberg T, Stolpman N, Calkins C, Everson GT, Kam I, Trotter J, University of Colorado Health Sciences Center, Denver, CO. OKT-3 does not increase the incidence of Lymphoproliferative disease after adult liver transplantation. *AASLD Annual Meeting*, October, 2000.
12. Trotter J, Wachs M, **Bak T**, Trouillot T, Everson GT, Kam I, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO. Liver Transplantation with Using Sirolimus and Three-Day Corticosteroid Taper. Accepted, *AASLD Annual Meeting*, October, 2000.
13. Trotter J, Wachs M, Trouillot T, **Bak T**, Everson GT, Kam I, Division of Gastroenterology and Hepatology, Division of Transplant Surgery, University of Colorado Health Sciences Center. The effect of living donor liver transplantation (LDLT) on median waiting times for UNOS status IIB cadaveric recipients at one center. Accepted, *AASLD Annual Meeting*, October, 2000.

14. **Thomas Bak**, University of Colorado Health Sciences Center. Living Liver Donation/Transplant. For the Fujisawa Healthcare, Inc.; San Diego, California, October 25, 2000.
15. Trotter JF, Wachs M, Trouillot TE, **Bak T**, Steinberg T, Everson GT, Kam I, University of Colorado Health Sciences Division of Gastroenterology/Hepatology/Transplant Surgery, Denver, CO. The evaluation of one-hundred potential recipients for liver donor liver transplantation. *AST Transplant 2000 Joint Meeting*.
16. **Thomas Bak**, University of Colorado Health Sciences Center. Hand-Assisted Laparoscopic Donor Nephrectomy: Advantages of this Modification of Standard Laparoscopic Approach. Poster-Presentation at the ERA-EDTA Congress; Nice, France, September 17-20, 2000.
17. Wachs M, **Bak T**, Everson GT, Trotter JF, Trouillot TE, Steinberg T, Kam I, Division of Transplant Surgery, UCHSC, Denver, CO. Adult to adult living donor liver transplants using a right hepatic lobe. *AST 2000 Joint Meeting*, May, 2000.
18. **Thomas Bak**, University of Colorado Health Sciences Center. Access when there is "No" access: Creative Surgical Access. Sponsored by Indiana University, Department of Medicine/Department of Nephrology. *Keystone*, Colorado, February 26, 2000.
19. Trouillot TE, Eckel R, Wachs M, Kam I, **Bak T**, Trotter JF, Everson GT, University of Colorado Health Sciences Transplant Surgery, Denver, CO. Patterns of dyslipidemia in patients on cyclosporine and tacrolimus monotherapy after liver transplantation. Submitted to *AST Transplant 2000 Joint Meeting*, 1999.
20. Wachs M, **Bak T**, Everson GT, Trotter JF, Trouillot TE, Steinberg T, Kam I, Division of Transplant Surgery, UCHSC, Denver, CO. Adult to Adult Living Donor Liver Transplants Using a Right Hepatic Lobe. *AST 2000 Joint Meeting*, May, 2000.
21. **Bak T**, Everson GT, Wachs M, Trouillot T, Kam I, Departments of Surgery and Hepatology. Living-donor liver transplantation for adults with fulminant failure (FHF): an under-utilized resource? *AST* May, 1999; *Liver Transplantation and Surgery*, October, 1999; *ILTS Program Abstracts*, 1999.
22. Thomas Trouillot, Tracy Steinberg, **Thomas Bak**, Michael Talamantes, Michael Wachs, Igal Kam, Gregory Everson. Quality of life (QOL) after liver transplantation: external validation of the NIDDK QOL instrument. University of Colorado Health Sciences Center. *International Liver Transplantation Society*: 1999.

23. Gregory Everson, Thomas Trouillot, Michael Wachs, **Thomas Bak**, Igal Kam, Ann Nedrow, Janet Stephens and the UCHSC Liver Transplant Group, Departments of Medicine, Surgery Pathology and Tumore Registry. Increased incidence of HCV-related hepatocellular (HCC) from 1988 to 1997 in the state of Colorado: Implications for liver transplantation (LTx). *American Society of Transplantation*: 1999.
24. Thomas Trouillot, Michael Wachs, Igal Kam, **Thomas Bak**, Gregory Everson. University of Colorado Health Sciences Center. Steady-state serum cholesterol levels after liver transplantation: effects of cyclosporine (CSA) and tacrolimus (TAC) monotherapy. *American Society of Transplantation*: 1999.
25. **TE Bak**, GT Everson, ME Wachs, TE Trouillot, I Kam. Living-Donor Liver Transplantation for Adults with Fulminant Hepatic Failure (FHF): An Under-Utilized Resource *ILTS Abstract* August 26-28, 1999.
26. S.Sato, GT Everson, TE Trouillot, M Chen, T. Steinberg, **T Bak**, ME Wachs, I Kam. Effect of Hepatitis C on Survival in Orthotopic Liver Transplant Recipients Undergoing Rapid Steroid Withdrawal. *ASTP Abstract* May 15-19, 1999.
27. Thomas Trouillot, Tracy Steinberg, **Thomas Bak**, Michael Talamantes, Michael Wachs. Quality of life (QOL) after liver transplantation: external validation of the NIDDK QOL instrument. *International Liver Transplant Society*, 1999.
28. Gregory Everson, Thomas Trouillot, Michael Wachs, **Thomas Bak**, Igal Kam, Ann Nedrow, Janet Stephens and the UCHSC Liver Transplant Group, Departments of Medicine, Surgery Pathology and Tumore Registry Increased incidence of HCV-related hepatocellular (HCC) from 1988 to 1997 in the state of Colorado: Implications for liver transplantation (LTx). *American Society of Transplantation*, May 1999.

#### **Book Chapters:**

1. Modanlou, K, Wachs M, Kam I, **Bak T**. Liver transplantation. In: McIntyre R Jr., Stiegmann G, Eiseman B, eds. *Surgical Decision Making, 5<sup>th</sup> ed.* Philadelphia. W.B. Saunders 2004.
2. Modanlou, K, Wachs M, Kam I, **Bak T**. Kidney transplantation. In: McIntyre R Jr., Stiegmann G, Eiseman B, eds. *Surgical Decision Making, 5<sup>th</sup> ed.* Philadelphia. W.B. Saunders 2004.
3. Modanlou, K, Wachs M, Kam I, **Bak T**. Jaundice. In: McIntyre R Jr., Stiegmann G, Eiseman B, eds. *Surgical Decision Making, 5<sup>th</sup> ed.* Philadelphia. W.B. Saunders 2004.
4. **Thomas E. Bak**, Michael E. Wachs, Igal Kam. Liver Transplantation. *Abernathy's Surgical Secrets*. Hanley & Belfus Inc, (Harken, A.H. and Moore



- E.E..) 5th edition. pp 315-317. (2003)
5. **Thomas E. Bak**, Michael E. Wachs, Igal Kam. Kidney and Pancreas Transplantation. Abernathy's Surgical Secrets. Hanley & Belfus Inc, (Harken, A.H.and Moore E.E..) 5th edition. pp 317-319. (2003)
  6. **Thomas E. Bak**, Michael E. Wachs, Igal Kam. Liver Transplantation. Abernathy's Surgical Secrets. Hanley & Belfus Inc, (Harken, A.H.and Moore E.E..) 4th edition. pp 289-290. (2000)
  7. **Thomas E. Bak**, Michael E. Wachs, Igal Kam. Kidney and Pancreas Transplantation. Abernathy's Surgical Secrets. Hanley & Belfus Inc, (Harken, A.H.and Moore E.E..) 4th edition. pp 290-292. (2000)

#### **Web-Based Chapters:**

1. Russ PD, Elliott DE, Durham JD, Garg K, Moubry R, Wachs ME, Kam I, **Bak TE**, Everson GT, Trotter J, Trouillot T, Kugelmas M: Liver Transplantation, Complications. *EMedicine Journal* {serial online}. 2002. Available at: <http://www.emedicine.com/radio/topic883.htm>

#### **Research**

1. Astellas Pharma US, Inc. Re: FK506E (Modified Release Formulation) IND #64,148 Safety Report Serial No. 318. PI. Oct. 2002 to present.